MDXH
Strong SellSinkerMDxHealth SA · Healthcare · Belgium · $69M · Avg Vol: $7M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT MDXHEALTH SA
Read
MDxHealth SA is a molecular diagnostics company dedicated to developing and commercializing advanced tests for prostate cancer. The company's competitive moat is built on its patented technologies, extensive clinical validation of its diagnostic assays, and the high regulatory and scientific barriers to entry in medical diagnostics. MDxHealth offers clinically proven solutions that help physicians make more informed decisions in prostate cancer diagnosis and management.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.2M | 37.1M | 70.2M | 90.0M | 107.9M | 48.4% | 114.0M | 113.4M | 128.4M | 9.1% |
| EPS | — | -0.89 | -1.66 | -1.16 | -0.67 | — | -0.71 | -0.46 | -0.38 | — |
| Shares | — | 51.4M | 27.3M | 49.5M | 51.4M | 0.0% | — | — | — | — |
| Debt | — | 39.8M | 41.3M | 60.1M | 86.6M | 29.6% | 105.8M | — | — | — |
| Equity | — | 9.3M | 7.2M | 14.8M | -12.1M | 26.2% | — | — | — | — |
| Op CF | — | -34.1M | -21.5M | -18.5M | -2.2M | — | -5.3M | — | — | — |
| Inv CF | — | -29.0M | -3.9M | -1.6M | -18.6M | — | — | — | — | — |
| Fin CF | — | 20.7M | 32.3M | 44.6M | 3.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDXH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MDXH | MDxHealth SA(you) | $69M | 13 | Strong Sell |
| SEQUA.BR | Sequana Medical NV | $54M | 13 | Strong Sell |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 14 | Strong Sell |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| IBAB.BR | Ion Beam Applications SA | $567M | 71 | Buy |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| LKFT | Lakefront Biotherapeutics NV | $1.9B | 68 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
Peer medians: ROE 5.0% · P/E 18.4x · Gross margin 60.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.